A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

for EuroSIDA in EuroCOORD

doi:10.1007/s15010-014-0630-4

A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

for EuroSIDA in EuroCOORD

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

5 Citations (Scopus)

Abstract

ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.

Original language	English
Journal	Infection
Volume	42
Issue	4
Pages (from-to)	757-762
Number of pages	6
ISSN	0300-8126
DOIs	https://doi.org/10.1007/s15010-014-0630-4
Publication status	Published - 1 Aug 2014

Access to Document

10.1007/s15010-014-0630-4

Cite this

@article{0ffba2f8a1b446fa9fdad89f53e89bc1,

title = "A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe",

abstract = "ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.",

author = "A. Mocroft and P. Reiss and A. Rakhmanova and D. Banhegyi and Phillips, {A. N.} and {De Wit}, S. and M. Ristola and Lundgren, {Jens D.} and J. Grarup and O. Kirk and M. Losso and M. Kundro and N. Vetter and R. Zangerle and I. Karpov and A. Vassilenko and O. Suetnov and N. Clumeck and M. Delforge and R. Colebunders and L. Vandekerckhove and V. Hadziosmanovic and K. Kostov and J. Begovac and L. Machala and D. Jilich and D. Sedlacek and J. Nielsen and G. Kronborg and T. Benfield and M. Larsen and J. Gerstoft and T. Katzenstein and Hansen, {A. B.E.} and P. Skinh{\o}j and C. Pedersen and L. Ostergaard and K. Zilmer and Jelena Smidt and R. Schmidt and J. Bruun and F. Antunes and M. Gutierrez and R. Weber and Johnson, {A. M.} and Johnson, {M. A.} and J. Weber and J. Kj{\ae}r and L. Peters and Fischer, {A. H.} and {for EuroSIDA in EuroCOORD}",

note = "Funding Information: Primary support for EuroSIDA is provided by the European Commission BIOMED 1 (CT94-1637), BIOMED 2 (CT97-2713), the 5th Framework (QLK2-2000-00773), the 6th Framework (LSHP-CT-2006-018632), and the 7th Framework (FP7/ 2007-2013, EuroCoord no 260694) programmes. Current support also includes unrestricted grants by BMS, Janssen R&D, Merck and Co. Inc., Pfizer Inc., GlaxoSmithKline LLC. The participation of centres from Switzerland was supported by The Swiss National Science Foundation (Grant 108787). This project was supported by an unrestricted grant from GlaxoSmithKline LLC. EuroSIDA maintained ownership of the data collected and analysed the data, and retained full responsibility for the study conduct and interpretation of the results. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",

year = "2014",

month = aug,

day = "1",

doi = "10.1007/s15010-014-0630-4",

language = "English",

volume = "42",

pages = "757--762",

journal = "Infection",

issn = "0300-8126",

publisher = "Urban und Vogel",

number = "4",

}

TY - JOUR

T1 - A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

AU - Mocroft, A.

AU - Reiss, P.

AU - Rakhmanova, A.

AU - Banhegyi, D.

AU - Phillips, A. N.

AU - De Wit, S.

AU - Ristola, M.

AU - Lundgren, Jens D.

AU - Grarup, J.

AU - Kirk, O.

AU - Losso, M.

AU - Kundro, M.

AU - Vetter, N.

AU - Zangerle, R.

AU - Karpov, I.

AU - Vassilenko, A.

AU - Suetnov, O.

AU - Clumeck, N.

AU - Delforge, M.

AU - Colebunders, R.

AU - Vandekerckhove, L.

AU - Hadziosmanovic, V.

AU - Kostov, K.

AU - Begovac, J.

AU - Machala, L.

AU - Jilich, D.

AU - Sedlacek, D.

AU - Nielsen, J.

AU - Kronborg, G.

AU - Benfield, T.

AU - Larsen, M.

AU - Gerstoft, J.

AU - Katzenstein, T.

AU - Hansen, A. B.E.

AU - Skinhøj, P.

AU - Pedersen, C.

AU - Ostergaard, L.

AU - Zilmer, K.

AU - Smidt, Jelena

AU - Schmidt, R.

AU - Bruun, J.

AU - Antunes, F.

AU - Gutierrez, M.

AU - Weber, R.

AU - Johnson, A. M.

AU - Johnson, M. A.

AU - Weber, J.

AU - Kjær, J.

AU - Peters, L.

AU - Fischer, A. H.

AU - for EuroSIDA in EuroCOORD

N1 - Funding Information: Primary support for EuroSIDA is provided by the European Commission BIOMED 1 (CT94-1637), BIOMED 2 (CT97-2713), the 5th Framework (QLK2-2000-00773), the 6th Framework (LSHP-CT-2006-018632), and the 7th Framework (FP7/ 2007-2013, EuroCoord no 260694) programmes. Current support also includes unrestricted grants by BMS, Janssen R&D, Merck and Co. Inc., Pfizer Inc., GlaxoSmithKline LLC. The participation of centres from Switzerland was supported by The Swiss National Science Foundation (Grant 108787). This project was supported by an unrestricted grant from GlaxoSmithKline LLC. EuroSIDA maintained ownership of the data collected and analysed the data, and retained full responsibility for the study conduct and interpretation of the results. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.

AB - ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.

UR - http://www.scopus.com/inward/record.url?scp=84906791021&partnerID=8YFLogxK

U2 - 10.1007/s15010-014-0630-4

DO - 10.1007/s15010-014-0630-4

M3 - Journal article

C2 - 24902520

AN - SCOPUS:84906791021

SN - 0300-8126

VL - 42

SP - 757

EP - 762

JO - Infection

JF - Infection

IS - 4

ER -

A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

Abstract

Access to Document

Other files and links

Fingerprint

Cite this